https://mavengity.com/categories/healthcare-medical/ Health insurance, medical billing, and healthcare cost articles from Mavengity, explained in plain English. en-us Wed, 28 Oct 2026 23:35:00 +0000 https://mavengity.com/assets/img/mavengity-yt-logo.png https://mavengity.com/categories/healthcare-medical/ https://mavengity.com/articles/healthcare-medical/hhs-peptide-compounding-enforcement-policy/ https://mavengity.com/articles/healthcare-medical/hhs-peptide-compounding-enforcement-policy/ Thu, 29 Oct 2026 00:00:00 +0000 healthcare-medical HHS told the FDA not to enforce compounding rules against six unproven peptides, opening a prescription supply route that most of the agency's drug scientists opposed. https://mavengity.com/articles/healthcare-medical/lilly-retatrutide-ozempic-head-to-head-transcend-t2d-2/ https://mavengity.com/articles/healthcare-medical/lilly-retatrutide-ozempic-head-to-head-transcend-t2d-2/ Wed, 28 Oct 2026 00:00:00 +0000 healthcare-medical Retatrutide cut A1C by 2.2 points and weight by about 21 percent over 80 weeks, beating semaglutide in TRANSCEND-T2D-2, though the open-label design and a wider tolerability gap complicate the claim. https://mavengity.com/articles/healthcare-medical/medicare-wiser-ai-prior-authorization-jama-study/ https://mavengity.com/articles/healthcare-medical/medicare-wiser-ai-prior-authorization-jama-study/ Wed, 28 Oct 2026 00:00:00 +0000 healthcare-medical A JAMA study of the WISeR pilot in six states found epidural steroid injections fell about 15 percent and other targeted services about 20 percent, while the authors caution the data cannot show whether the care was necessary. https://mavengity.com/articles/healthcare-medical/onc-hti-5-final-rule-certification-criteria-cuts/ https://mavengity.com/articles/healthcare-medical/onc-hti-5-final-rule-certification-criteria-cuts/ Wed, 28 Oct 2026 00:00:00 +0000 healthcare-medical The HTI-5 final rule removes 14 of 60 certification criteria, drops the AI model card requirement, and projects $1.55 billion in savings. https://mavengity.com/articles/healthcare-medical/la-health-care-fraud-takedown-billing-outliers/ https://mavengity.com/articles/healthcare-medical/la-health-care-fraud-takedown-billing-outliers/ Fri, 23 Oct 2026 00:00:00 +0000 healthcare-medical Fifteen defendants, six medical professionals, and schemes that paid for codes rather than care. The cases show the payment system's own data becoming the detection system. https://mavengity.com/articles/healthcare-medical/compounded-tirzepatide-recall-sterility-shortage-end/ https://mavengity.com/articles/healthcare-medical/compounded-tirzepatide-recall-sterility-shortage-end/ Wed, 21 Oct 2026 00:00:00 +0000 healthcare-medical A small tirzepatide recall points to a larger problem: the compounding market that grew during the GLP-1 shortage is still selling, even though the shortage that justified it has largely ended. https://mavengity.com/articles/healthcare-medical/transformative-healthcare-masshealth-breach-settlement/ https://mavengity.com/articles/healthcare-medical/transformative-healthcare-masshealth-breach-settlement/ Tue, 20 Oct 2026 00:00:00 +0000 healthcare-medical Massachusetts reached a $1 million settlement with Transformative Healthcare over alleged ambulance upcoding and a 2023 breach that exposed the data of 750,116 residents, years after the company stopped operating. https://mavengity.com/articles/healthcare-medical/sensorion-hearing-loss-gene-therapy/ https://mavengity.com/articles/healthcare-medical/sensorion-hearing-loss-gene-therapy/ Fri, 09 Oct 2026 00:00:00 +0000 healthcare-medical Sensorion's SENS-601 is cleared for trials in France against the most common genetic cause of deafness. The biology is arriving on schedule; the payment models are not. https://mavengity.com/articles/healthcare-medical/health-care-cybersecurity-resilience-act-senate-passage/ https://mavengity.com/articles/healthcare-medical/health-care-cybersecurity-resilience-act-senate-passage/ Sat, 03 Oct 2026 00:00:00 +0000 healthcare-medical The Senate passed the Health Care Cybersecurity and Resilience Act by unanimous consent, directing HHS to set minimum cybersecurity practices for hospitals and clinics through the HIPAA Security Rule, with the grants it creates left to a later spending vote. https://mavengity.com/articles/healthcare-medical/medicare-improvement-fund-90-dollar-payments-authority/ https://mavengity.com/articles/healthcare-medical/medicare-improvement-fund-90-dollar-payments-authority/ Sat, 03 Oct 2026 00:00:00 +0000 healthcare-medical The administration is sending one-time payments of $90 to more than 20 million Medicare enrollees out of a fund Congress created to improve the fee-for-service program, and the statute describes a different kind of spending than the checks going out this month. https://mavengity.com/articles/healthcare-medical/agomab-ontunisertib-fibrostenosing-crohns-open-label-extension/ https://mavengity.com/articles/healthcare-medical/agomab-ontunisertib-fibrostenosing-crohns-open-label-extension/ Fri, 02 Oct 2026 00:00:00 +0000 healthcare-medical Agomab's open-label extension in fibrostenosing Crohn's disease recorded one balloon dilation and no surgeries across 49 patients, a count of absent events rather than a controlled comparison. https://mavengity.com/articles/healthcare-medical/astrazeneca-summit-ivonescimab-datroway-combination-trial/ https://mavengity.com/articles/healthcare-medical/astrazeneca-summit-ivonescimab-datroway-combination-trial/ Fri, 02 Oct 2026 00:00:00 +0000 healthcare-medical AstraZeneca put $2 billion into Summit Therapeutics for roughly 12 percent of the company and no royalty on ivonescimab, then signed a combination trial whose Phase 3 will be sponsored by AstraZeneca or Daiichi Sankyo. https://mavengity.com/articles/healthcare-medical/globe-model-final-rule-part-b-inflation-rebate-savings/ https://mavengity.com/articles/healthcare-medical/globe-model-final-rule-part-b-inflation-rebate-savings/ Fri, 02 Oct 2026 00:00:00 +0000 healthcare-medical CMS finalized the GLOBE model with projected savings of roughly $80 million a year, down from $2.3 billion when it was proposed, after excluding orphan drugs, cell and gene therapies and plasma products and waiving manufacturers enrolled in a separate Medicaid model. https://mavengity.com/articles/healthcare-medical/iqvia-garante-health-data-anonymity-fine/ https://mavengity.com/articles/healthcare-medical/iqvia-garante-health-data-anonymity-fine/ Fri, 02 Oct 2026 00:00:00 +0000 healthcare-medical Italy's privacy regulator fined IQVIA's Italian unit seven million euros over a health database covering a million patients that the company had treated as anonymous, the second European authority to reject that claim about the same company's data. https://mavengity.com/articles/healthcare-medical/nektar-rezpegaldesleukin-alopecia-off-treatment-durability/ https://mavengity.com/articles/healthcare-medical/nektar-rezpegaldesleukin-alopecia-off-treatment-durability/ Fri, 02 Oct 2026 00:00:00 +0000 healthcare-medical Nektar's Phase 2b alopecia areata data show hair regrowth that kept deepening for six months after the last dose, with the durability comparison resting on eight patients. https://mavengity.com/articles/healthcare-medical/autus-size-adjustable-pulmonary-valve-pediatric-approval/ https://mavengity.com/articles/healthcare-medical/autus-size-adjustable-pulmonary-valve-pediatric-approval/ Thu, 01 Oct 2026 00:00:00 +0000 healthcare-medical The FDA cleared the Autus Size-Adjustable Valve for children with congenital pulmonary valve disease, the first heart valve approved for expansion after implantation and the first approved with synthetic leaflets, on six-month results from 62 patients. https://mavengity.com/articles/healthcare-medical/connect-biopharma-rademikibart-copd-asthma-endpoint-split/ https://mavengity.com/articles/healthcare-medical/connect-biopharma-rademikibart-copd-asthma-endpoint-split/ Thu, 01 Oct 2026 00:00:00 +0000 healthcare-medical Rademikibart cut COPD treatment failure 81 percent over 28 days in a 159-patient Phase 2 trial, three weeks after the same endpoint missed in asthma. Connect Biopharma now has to settle with the FDA which measure a Phase 3 would be built on. https://mavengity.com/articles/healthcare-medical/counterfeit-ozempic-supply-chain-indictment/ https://mavengity.com/articles/healthcare-medical/counterfeit-ozempic-supply-chain-indictment/ Wed, 30 Sep 2026 00:00:00 +0000 healthcare-medical Two men are charged with running counterfeit Ozempic from Chinese suppliers into U.S. distributors, a scheme prosecutors say continued after the FDA seized fakes and warned the public. https://mavengity.com/articles/healthcare-medical/dyne-z-basivarsen-achieve-one-year-dm1/ https://mavengity.com/articles/healthcare-medical/dyne-z-basivarsen-achieve-one-year-dm1/ Wed, 30 Sep 2026 00:00:00 +0000 healthcare-medical Z-basivarsen improved hand myotonia and function against a matched natural history cohort at 12 months, and the endpoint carrying its accelerated approval is the one that just failed for the field's biggest program. https://mavengity.com/articles/healthcare-medical/emcitate-tiratricol-mct8-deficiency-first-approval/ https://mavengity.com/articles/healthcare-medical/emcitate-tiratricol-mct8-deficiency-first-approval/ Wed, 30 Sep 2026 00:00:00 +0000 healthcare-medical The FDA approved Emcitate (tiratricol) on Sept. 28 for peripheral thyrotoxicosis in MCT8 deficiency, the first therapy cleared for the X-linked disorder. The trial behind the approval randomized 15 patients for 30 days, the label directs doctors to a T3 test few laboratories offer, and the same molecule was sold as a weight-loss supplement until the FDA warned consumers off it in 1999.